Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: A propensity-matched analysis of in-hospital outcomes

Abstract

AimsTo estimate if chronic anticoagulant (CAC) treatment is associated with morbidity and mortality outcomes of patients hospitalized for SARS-CoV-2 infection.MethodsIn this European multicentric cohort study, we included 1186 patients of whom 144 were on CAC (12.1%) with positive coronavirus disease 2019 testing between 1 February and 30 July 2020. The average treatment effect (ATE) analysis with a propensity score-matching (PSM) algorithm was used to estimate the impact of CAC on the primary outcomes defined as in-hospital death, major and minor bleeding events, cardiovascular complications (CCI), and acute kidney injury (AKI). We also investigated if different dosages of in-hospital heparin were associated with in-hospital survival.ResultsIn unadjusted populations, primary outcomes were significantly higher among CAC patients compared with non-CAC patients: All-cause death (35% vs. 18% P-